SCHEMBL17485263

SCHEMBL17485263

ClC/C=C/c1cccc(/C=C/CCl)c1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 3/20 0.41
FBP1 P09467 1/20 0.40
CYP19A1 P11511 2/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
LCK P06239 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
GFER P55789 1/20 0.36
APP P05067 2/20 0.36
IDO1 P14902 1/20 0.35
PAM P19021 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28823543 0.89 ALDH1A1 (0.45) FBP1MAOAMAOBCHRM2CHRM1
SCHEMBL2772413 0.87 CYP1A2 (0.53) NFE2L2FBP1MAOAMAOBCYP1A2
SCHEMBL2772409 0.87 CYP1A2 (0.53) NFE2L2FBP1MAOAMAOBCYP1A2
SCHEMBL79771 0.85 PTGS1 (0.50) NFE2L2FBP1MAOAMAOBCYP1A2
SCHEMBL10901883 0.85 HSD17B3 (0.52) MAOAMAOBMAPT
SCHEMBL79770 0.85 PTGS1 (0.50) NFE2L2FBP1MAOAMAOBCYP1A2
SCHEMBL27792900 0.85 LCK (0.59) FBP1MAOAMAOBLCKCYP1A2
SCHEMBL9871756 0.85 NFE2L2 (0.65) NFE2L2FBP1CYP1A2NPC1
SCHEMBL10901886 0.85 HSD17B3 (0.52) MAOAMAOBMAPT
SCHEMBL7294478 0.85 NFE2L2 (0.65) NFE2L2FBP1CYP1A2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11013760-B2 Polyguanidine polymers and methods of use thereof SEALIFE PHARMA GMBH (AT) 2021-05-25 US disclosed
US-11013760-B2 Polyguanidine polymers and methods of use thereof SEALIFE PHARMA GMBH (AT) 2021-05-25 US disclosed
US-20190269719-A1 POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF SEALIFE PHARMA GMBH (AT) 2019-09-05 US disclosed
US-20190269719-A1 POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF SEALIFE PHARMA GMBH (AT) 2019-09-05 US disclosed
US-10335431-B2 Method for producing polyguanidines SEALIFE PHARMA GMBH (AT) 2019-07-02 US disclosed
EP-3174848-B1 METHOD FOR PRODUCING POLYGUANIDINES SEALIFE PHARMA GMBH (AT) 2018-08-01 EP disclosed
EP-3174848-B1 METHOD FOR PRODUCING POLYGUANIDINES SEALIFE PHARMA GMBH (AT) 2018-08-01 EP disclosed
US-20170224723-A1 METHOD FOR PRODUCING POLYGUANIDINES SEALIFE PHARMA GMBH (AT) 2017-08-10 US disclosed
US-20170224723-A1 METHOD FOR PRODUCING POLYGUANIDINES SEALIFE PHARMA GMBH (AT) 2017-08-10 US disclosed
WO-2016015081-A9 METHOD FOR PRODUCING POLYGUANIDINES SEALIFE PHARMA GMBH (AT) 2016-03-31 WO disclosed
WO-2016015081-A1 METHOD FOR PRODUCING POLYGUANIDINES SEALIFE PHARMA GMBH (AT) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10335431-B2 Method for producing polyguanidines GDA, PARG, ADAR NFE2L2 3495/4885FBP1 1577/4885CYP19A1 3660/4885
US-20190269719-A1 POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF PUF60, PARG, ALG1 NFE2L2 4758/4885FBP1 666/4885CYP19A1 4505/4885
US-11013760-B2 Polyguanidine polymers and methods of use thereof PUF60, PARG, ALG1 NFE2L2 4758/4885FBP1 666/4885CYP19A1 4505/4885
US-20170224723-A1 METHOD FOR PRODUCING POLYGUANIDINES GDA, PARG, ADAR NFE2L2 3495/4885FBP1 1577/4885CYP19A1 3660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.